Ziwig is a French biotechnology company based in Lyon, which was founded in 2019 and now has around one hundred employees. It carries out a very strong research activity in direct link with healthcare professionals for the benefit of patients in order to develop precision medicine tools and practices and thus transform healthcare systems for the benefit of everyone.

Ziwig specialises in the analysis of saliva, the extraction of information in particular by new-generation sequencing (NGS) and its processing, with or without comparison with other data (omics) including real-life data, using artificial intelligence algorithms.

The combination of these resources makes it possible to define expression profiles for the RNAs contained in saliva and thus to use non-invasive saliva tests, which can be carried out simply at any point in the territory, to sign off on diagnoses, prognoses, conditions, sensitivities or resistances to certain treatments.

Ziwig is a biotechnology company. Since its creation, it has focused its initial achievements on women’s health, particularly endometriosis. Its technology is agnostic. Numerous studies and clinical trials are underway in other therapeutic areas, notably oncology and neurology.

Ziwig is a biotechnology company that uses disruptive technology to provide a range of services, including the production of diagnostic tests. It is not a biological laboratory for medical analysis. Nor is it a pharmaceutical company. However, these 2 entities, like many others, form the ecosystem required for the development and use of the company’s technologies and products.

E4i (https://www.e4i.health) is an endowment fund that helps to structure and organise an ecosystem for exchanging ideas and promoting precision medicine and women’s health, while remaining totally independent of the company’s commercial activities. Endowment fund status prohibits any advertising or commercial activity.